Summary: In a single-center randomized controlled trial of 180 adults with type 2 diabetes, an integrated cloud-hospital data platform delivering individualized education videos plus dietary management was compared with routine standard care over 12 weeks. HbA1c at Week 12 was lower in the platform group (6.9 plus or minus 0.9%) than in the control group (7.4 plus or minus 0.7%), P less than 0.01, with greater weight loss confined to an overweight or obese subgroup, most of which was driven by concurrent semaglutide use.
PICO Summary
| Element | Detail |
|---|---|
| Population | 180 adults with type 2 diabetes; single-center, prospective parallel-group randomized controlled trial; China. |
| Intervention | Integrated cloud-hospital data platform plus dietary management, with individualized diabetes education videos delivered through the platform (Group B, n approximately 90). Within this arm, some overweight or obese patients additionally received semaglutide. |
| Comparison | Routine standard diabetes care without the platform or video intervention (Group A, n approximately 90). |
| Outcome | Co-primary endpoints were change in HbA1c and body weight at Week 12. HbA1c: 6.9 plus or minus 0.9% (platform) versus 7.4 plus or minus 0.7% (control), an absolute between-group difference of about 0.5 percentage points, P less than 0.01 (95% CI not reported). A higher proportion of the platform group reached fasting glucose below 7 mmol/L and HbA1c below 7%. Significant weight and BMI reduction occurred only in the overweight or obese subgroup of the platform arm; the maximal 13.4% weight loss at 12 weeks was seen specifically in those who also took semaglutide. No ARR, NNT, or confidence intervals were reported. |
Digital data platform plus dietary management in type 2 diabetes
RCT · type 2 diabetes · 12 weeks
A cloud-hospital platform plus dietary management lowered Week 12 HbA1c to 6.9% versus 7.4% with standard care (P < 0.01). The single-center, open-label design and a semaglutide-driven weight signal limit the strength of this evidence.
Expert Commentary
The trial offers cautiously encouraging evidence that a structured digital data platform plus dietary support can improve short-term glycemic control relative to routine care, with a statistically significant Week 12 HbA1c separation of roughly half a percentage point. The verdict, however, is that this is a small, single-center, open-label study of modest duration, and its headline weight-loss figure must be read with care. The dominant limitation is that the striking 13.4% weight reduction was not a property of the platform at all; it was observed in an unrandomized subgroup of overweight or obese participants who additionally received semaglutide, a potent pharmacologic agent whose effect is being conflated with the digital intervention. The glycemic benefit itself, while real, may be inflated by the open-label design, by the inherent attention and engagement effect of a high-touch video platform, and by the absence of reported confidence intervals or formal adjustment for the semaglutide co-intervention. Can I use this with my patients? Tentatively, for motivated adults with type 2 diabetes who can engage with app-based education and dietary coaching as an adjunct to usual care, but not as a substitute for established therapy, and not on the basis of the semaglutide-driven weight figure. Larger, multicenter, longer trials that separate the platform effect from concurrent pharmacotherapy are needed before this can be recommended as a standalone management mode.
References
Liu X, Wang X, Xie M, Cao L. Application of the integrated data platform combined with dietary management for adults with diabetes: A prospective randomized controlled trial. J Diabetes Investig. 2024;15(11):1548-1555. doi:10.1111/jdi.14296